Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs

Related articles

Photo of the Eclipsebio team

eBlogs

11
14
24

2024 Thanksgiving Message from the CEO

Our CEO, Peter Chu, reflects on the successes of the past year and looks forward to 2025 in this Thanksgiving-themed eBlog.

read more
Cartoon schematic showing the different regions of an siRNA and how siRNAs can have off-target binding.

eBlogs

10
18
24

Reducing off-target effects in siRNA: expert tips for better efficacy

In this eBlog we discuss the mechanisms of siRNA off-target interactions and outlines strategies to minimize them.

read more
Cartoon showing the different types of RNA secondary structures such as loops and stems

eBlogs

09
14
24

RNA structure analysis for improved drug development

RNA secondary structure is a key determinant of RNA biology and therapeutic efficacy. In this eBlog, we review how RNA structure affects the development of RNA vaccines, siRNAs, and ASOs.

read more

Press Releases

09
03
24

Eclipsebio Expands eMERGE™ Platform with eSENSE dsRNA™ for dsRNA Quantification and Localization

SAN DIEGO, September 3, 2024 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in developing precision solutions for RNA-based and RNA-targeting therapeutics, today announced the launch of its eSENSE dsRNA™ assay. eSENSE dsRNA is a next-generation sequencing method for the robust quantification, localization, and optimization of double-stranded RNA (dsRNA) contaminants in RNA-based vaccines and therapeutics. “By […]

read more